Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Neurogene (NGNE) Invested Capital (2018 - 2025)

Historic Invested Capital for Neurogene (NGNE) over the last 6 years, with Q3 2025 value amounting to $265.5 million.

  • Neurogene's Invested Capital rose 9311.02% to $265.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $265.5 million, marking a year-over-year increase of 9311.02%. This contributed to the annual value of $310.5 million for FY2024, which is 6679.38% up from last year.
  • Latest data reveals that Neurogene reported Invested Capital of $265.5 million as of Q3 2025, which was up 9311.02% from $273.3 million recorded in Q2 2025.
  • In the past 5 years, Neurogene's Invested Capital ranged from a high of $310.5 million in Q4 2024 and a low of $75.2 million during Q3 2023
  • For the 3-year period, Neurogene's Invested Capital averaged around $184.3 million, with its median value being $170.9 million (2024).
  • Examining YoY changes over the last 5 years, Neurogene's Invested Capital showed a top increase of 11002.86% in 2024 and a maximum decrease of 6679.38% in 2024.
  • Quarter analysis of 3 years shows Neurogene's Invested Capital stood at $186.1 million in 2023, then surged by 66.79% to $310.5 million in 2024, then fell by 14.47% to $265.5 million in 2025.
  • Its Invested Capital was $265.5 million in Q3 2025, compared to $273.3 million in Q2 2025 and $291.8 million in Q1 2025.